摘要
目的 分析盐酸替罗非班对非ST段抬高型急性冠脉综合征患者血小板聚集率及预后的影响。方法 选择2017年8月至2019年8月我院收治的96例非ST段抬高型急性冠脉综合征患者为研究对象,根据电脑盲选法将其分为对照组(n=48,常规治疗)与研究组(n=48,盐酸替罗非班+常规治疗)。比较两组的治疗效果。结果 治疗48 h后,研究组的蛋白酶活化受体(PAR)、血管性血友病因子(vWF)、内皮素(ET)水平、血小板聚集率低于对照组(P<0.05)。治疗48 h后,研究组的可溶性细胞间黏附分子-1(sICAM-1)、超敏C反应蛋白(hs-CRP)水平及中性粒细胞与淋巴细胞比值(NLR)低于对照组(P<0.05)。治疗30 d后,研究组的不良心血管事件总发生率低于对照组(P<0.05)。结论 盐酸替罗非班治疗非ST段抬高型急性冠脉综合征的效果良好,临床可进一步推广运用。
Objective To analyze the effects of tirofiban hydrochloride on platelet aggregation rate and prognosis in patients with non-ST-segment elevation acute coronary syndrome. Methods Ninety-six patients with non-ST-segment elevation acute coronary syndrome admitted in our hospital from August 2017 to August 2019 were selected as the research objects. According to the computer blind selection method, the patients were divided into control group(n =48, routine treatment) and study group(n=48, tirofiban hydrochloride + routine treatment). The therapeutic effects of the two groups were compared. Results After 48 h of treatment, the protease-activated receptor(PAR), von Willebrand factor(v WF),endothelin(ET) level and platelet aggregation rate in the study group were lower than those in the control group(P<0.05).After 48 h of treatment, the levels of soluble intercellular adhesion molecule-1(sICAM-1), high sensitivity C-reactive protein(hs-CRP) and neutrophil-to-lymphocyte ratio(NLR) in the study group were lower than those in the control group(P<0.05). After 30 d of treatment, the total incidence of adverse cardiovascular events in the study group was lower than that in the control group(P<0.05). Conclusion Tirofiban hydrochloride is effective in the treatment of non-ST-segment elevation acute coronary syndrome, which can be further promoted in clinical practice.
作者
袁旭
张磊
YUAN Xu;ZHANG Lei(Emergency Department,Pingdingshan the Second People's Hospital,Pingdingshan 467000,China)
出处
《临床医学研究与实践》
2023年第8期24-26,共3页
Clinical Research and Practice
关键词
非ST段抬高型急性冠脉综合征
盐酸替罗非班
血小板聚集率
non-ST-segment elevation acute coronary syndrome
tirofiban hydrochloride
platelet aggregation rate
